Evidence review · standard
selank metformin
Regeneration vs degeneration — where this fits
metformin represents tissue breakdown exceeding repair capacity. Most interventions manage symptoms. This article examines whether selank mechanisms address underlying repair deficits.
What is known
Studied for anxiolytic pathways without classic benzodiazepine sedation.
Target condition: metformin. Body system: Metabolic tool; B12/mitochondrial concerns at chronic use — context dependent..
Logic chain
- selank studied for anxiolytic pathways without classic benzodiazepine sedation..
- metformin involves metabolic tool; b12/mitochondrial concerns at chronic use — context dependent. dysfunction.
- If selank reaches the affected tissue, it may shift the repair/breakdown balance.
- This chain is tested in animal or lab models only.
Parent peptide claims relevant here
- In a 2008 randomized study of 62 patients with GAD and neurasthenia, Selank showed anxiolytic efficacy comparable to medazepam on psychometric scales without reported sedation, cognitive impairment, tolerance or withdrawal.
- Selank administration in rats alters expression of 45 neurotransmission-related genes at 1 hour and 22 genes at 3 hours, with positive correlation to GABA effects.
- Commercial vendors and clinics market this compound (7 commercial/clinic sources catalogued) — marketing material, not evidence.
- 2017 study showing Selank's anxiolytic effects comparable to benzodiazepines in rat stress model.
- 2019 rat study on Selank protecting against alcohol-related memory issues via BDNF regulation.
Evidence tier
Preclinical — animal and in vitro studies only. No published human trials for this specific combination.
What we do not know
- Whether selank reaches metformin tissue at functional concentrations
- Optimal dosing, route, and duration for this target
- Interaction with standard-of-care treatments for metformin
- Long-term safety profile in this population
Safety note
All peptide use for metformin is research-context only. Not medical advice. Consult a physician before any experimental compound.
Key evidence
system
Combinatorial mapping (transparent): selank vs metformin — regen=0.17, degen=0.25, Δ=-0.08. Method: layer_relevance(0.20) × evidence_factor(0.85); catalog.degen_score for Metformin.
Model review1 contributions · 1 modelExpand the recursive review layer
1 / 1
Machine verification:
/api/articles/selank-metformin/contributionsAsk this article · 3 suggested prompts
Text the build (+14245134626) or WhatsApp — slug|question creates a question node. Paste evidence with ingest slug|q:NODE_ID|your paste.
What does the ledger say about this (system tier): "Combinatorial mapping (transparent): selank vs metformin — regen=0.17, degen=0.25, Δ=-0.08. Method: layer_relevance(0.20) × evidence_factor(…"?
ask selank-metformin claim c_map_selank-metformin · paste includes §SELF
For my medical situation, what can you answer from your catalogue about selank metformin — and what would you need me to tell you first?
ask selank-metformin condition gaps · paste includes §SELF
What good and bad outcomes are documented for selank metformin (studies vs anecdotes)?
ask selank-metformin good bad experiences · paste includes §SELF